文献速递妇科

体细胞分子谱分析对罕见上皮性妇科肿瘤患者临床试验结局的影响

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
PubMed 文献 · Gynecol Oncol · 2019-02-18

研究评估了罕见上皮性妇科肿瘤患者通过机构分子谱分析项目检测体细胞变异的可行性及临床效用,2012年3月至2015年11月共入组767例妇科患者,其中194例(27%)被归类为罕见上皮性恶性肿瘤。72%的患者检出至少一种体细胞突变,最常见于TP53(39%)、KRAS(28%)和PIK3CA(27%),14%的患者接受了基因型匹配试验治疗,基因型匹配与不匹配试验的总体缓解率无显著差异,基因型试验与既往系统标准治疗的中位治疗时间也无显著差异。

要点

  • 194例(27%)罕见上皮性妇科肿瘤患者中,72%检出至少一种体细胞突变。
  • 14%的患者接受了基因型匹配临床试验治疗。
  • 基因型匹配与不匹配试验的总体缓解率无显著差异。

核心结论

  • 体细胞分子谱分析可行,能够识别罕见妇科肿瘤中适合基因型匹配临床试验的患者。
  • 基因型匹配试验(主要为KRAS和/或NRAS突变低级别浆液性卵巢癌患者中的MEK抑制剂联合方案)与基因型不匹配试验均显示出潜在临床活性。
  • 作者认为需要开展整合基因分型的前瞻性试验,以评估下一代测序检测作为罕见恶性肿瘤标准临床应用的价值。

研究设计与样本

  • 通过机构分子谱分析项目,使用Sequenom MassArray平台或MiSeq平台上的TruSeq Amplicon Cancer Panel对罕见上皮性妇科肿瘤患者进行体细胞变异分析。
  • 评估指标包括按RECIST 1.1标准判定的临床试验结局和治疗时间。
  • 2012年3月至2015年11月共入组767例妇科患者,其中194例(27%)被归类为罕见上皮性恶性肿瘤。

主要发现

  • 72%的患者检出至少一种体细胞突变,最常见于TP53(39%)、KRAS(28%)和PIK3CA(27%)。
  • 14%的患者接受了基因型匹配试验治疗。
  • 基因型匹配试验与不匹配试验的总体缓解率无显著差异。
  • 基因型试验与既往系统标准治疗的中位治疗时间无显著差异。
  • 13例可评估的低级别浆液性卵巢癌患者接受基于MEK抑制剂的基因型匹配靶向联合方案治疗,其中4例达到部分缓解。

关键数值与推荐

  • 罕见上皮性恶性肿瘤患者占入组妇科患者的194/767(27%)。
  • 至少一种体细胞突变检出率为72%,TP53突变率39%,KRAS突变率28%,PIK3CA突变率27%。
  • 基因型匹配试验治疗率为14%。
  • 13例可评估低级别浆液性卵巢癌患者中4例部分缓解。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Conducting clinical trials in rare malignancies is challenging due to the limited number of patients and differences in biologic behavior. We investigated the feasibility and clinical utility of using genomic profiling for rare gynecologic malignancies. METHODS: Rare epithelial gynecologic cancer patients were analyzed for somatic variants through an institutional molecular profiling program using the Sequenom MassArray platform or the TruSeq Amplicon Cancer Panel on the MiSeq platform. Clinical trial outcomes by RECIST 1.1, and time on treatment were evaluated. RESULTS: From March 2012 to November 2015, 767 gynecologic patients were enrolled and 194 (27%) were classified as rare epithelial malignancies. At least one somatic mutation was identified in 72% of patients, most commonly in TP53 (39%), KRAS (28%) and PIK3CA (27%). A total of 14% of patients were treated on genotype-matched trials. There were no significant differences in overall response rate between genotype-matched versus unmatched trials, nor in median time on treatment between genotype trials and the immediate prior systemic standard treatment. Among 13 evaluable Low Grade Serous ovarian cancer patients treated on genotype-matched trials with MEK inhibitor-based targeted combinations, there were four partial responses. CONCLUSIONS: Somatic molecular profiling is feasible and enables the identification of patients with rare gynecologic cancers who are candidates for genotype-matched clinical trials. Genotype-matched trials, predominantly MEK-based combinations in KRAS and/or NRAS mutant Low Grade Serous ovarian cancer patients, and genotype-unmatched trials, have shown potential clinical activity. Prospective trials with integrated genotyping are warranted to assess the clinical utility of next generation sequencing tests as a standard clinical application in rare malignancies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Freixinos V, Lheureux S, Mandilaras V, et al. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecol Oncol. 2019. PMID: 30792002. doi:10.1016/j.ygyno.2019.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。